Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Psychiatry

PDF

2015

Akathisia;; clinical trial;; metabolic side effects;; negative symptoms;; treatment response

Articles 1 - 1 of 1

Full-Text Articles in Medicine and Health Sciences

A Randomized Comparison Of Aripiprazole And Risperidone For The Acute Treatment Of First-Episode Schizophrenia And Related Disorders: 3-Month Outcomes, D. G. Robinson, J. A. Gallego, M. John, G. Petrides, Y. Hassoun, J. P. Zhang, L. Lopez, R. J. Braga, M. Naraine, N. Bennett, J. Greenberg, T. Lencz, C. U. Correll, J. M. Kane, A. K. Malhotra, +4 Additional Authors Jan 2015

A Randomized Comparison Of Aripiprazole And Risperidone For The Acute Treatment Of First-Episode Schizophrenia And Related Disorders: 3-Month Outcomes, D. G. Robinson, J. A. Gallego, M. John, G. Petrides, Y. Hassoun, J. P. Zhang, L. Lopez, R. J. Braga, M. Naraine, N. Bennett, J. Greenberg, T. Lencz, C. U. Correll, J. M. Kane, A. K. Malhotra, +4 Additional Authors

Journal Articles

Research findings are particularly important for medication choice for first-episode patients as individual prior medication response to guide treatment decisions is unavailable. We describe the first large-scale double-masked randomized comparison with first-episode patients of aripiprazole and risperidone, 2 commonly used first-episode treatment agents. One hundred ninety-eight participants aged 15-40 years with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder Not Otherwise Specified, and who had been treated in their lifetime with antipsychotics for 2 weeks or less were randomly assigned to double-masked aripiprazole (5-30mg/d) or risperidone (1-6mg/d) and followed for 12 weeks. Positive symptom response rates did not differ (62.8% …